Sugi Predict

Sugi Predict / Compounds / SCHEMBL2885499

SCHEMBL2885499

SCHEMBL2885499

NCc1nc2ccccc2c(=O)[nH]1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TNKS2 Q9H2K2 3/20 0.70
▸ KMT2A Q03164 2/20 0.68
▸ PDE10A Q9Y233 2/20 0.64
▸ PARP1 P09874 4/20 0.62
▸ RAB9A P51151 2/20 0.62
▸ PARP2 Q9UGN5 1/20 0.62
▸ QTRT1 Q9BXR0 1/20 0.61
▸ POLB P06746 1/20 0.60
▸ RET P07949 1/20 0.60
▸ KDR P35968 1/20 0.60
▸ KDM4E B2RXH2 2/20 0.59
▸ LMNA P02545 1/20 0.59
▸ MAPT P10636 1/20 0.59
▸ MEN1 O00255 1/20 0.59
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ NPC1 O15118 1/20 0.55
▸ TNKS O95271 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30259339 1.00 TNKS2 (0.70) TNKS2KMT2APDE10APARP1RAB9A
Hydrochloric Acid SCHEMBL2883921 0.98 TNKS2 (0.68) TNKS2KMT2APDE10APARP1RAB9A
SCHEMBL1914469 0.86 PDE10A (0.69) TNKS2KMT2APDE10APARP1RAB9A
SCHEMBL31397021 0.86 PDE10A (0.69) TNKS2KMT2APDE10APARP1RAB9A
SCHEMBL16404338 0.85 PDE10A (0.84) TNKS2KMT2APDE10APARP1RAB9A
Hydrochloric Acid SCHEMBL15575309 0.85 PDE10A (0.68) TNKS2KMT2APDE10APARP1RAB9A
SCHEMBL6791216 0.83 PARP1 (0.73) TNKS2KMT2APDE10APARP1RAB9A
SCHEMBL19673854 0.82 TNKS2 (0.70) TNKS2KMT2APDE10APARP1RAB9A
SCHEMBL1685046 0.82 TNKS2 (0.70) TNKS2KMT2APDE10APARP1RAB9A
SCHEMBL3985227 0.82 TNKS2 (0.70) TNKS2KMT2APDE10APARP1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150978-A1 QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER ENYO PHARMA (FR) 2023-05-18 — — US disclosed
EP-4126847-A1 QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER ENYO Pharma (FR) 2023-02-08 — — EP disclosed
WO-2021198191-A1 QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER ENYO PHARMA (FR) 2021-10-07 — — WO disclosed
WO-2021198188-A1 QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER ENYO PHARMA (FR) 2021-10-07 — — WO disclosed
EP-3052099-B1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2019-08-21 — — EP disclosed
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 — — US disclosed
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 — — US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 — — US disclosed
WO-2015050798-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2015-04-09 — — WO disclosed
EP-1954135-B1 SPIROLACTAM ARYL CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2012-10-10 — — EP disclosed
US-20100267633-A1 N-(4-Oxo-3,4-Dihydroquinazolin-2Yl) Butanamides as Androgen Receptor Modulators MERCK SHARP & DOHME CORP. 2010-10-21 — — US disclosed
US-20090247514-A1 Spirolactam aryl cgrp receptor antagonists MERCK SHARP & DOHME LLC 2009-10-01 — — US disclosed
US-20090247514-A1 Spirolactam aryl cgrp receptor antagonists MERCK SHARP & DOHME LLC 2009-10-01 — — US disclosed
US-20090239870-A1 Spirohydantoin Aryl Cgrp Receptor Antagonists MERCK SHARP & DOHME LLC 2009-09-24 — — US disclosed
US-20090239870-A1 Spirohydantoin Aryl Cgrp Receptor Antagonists MERCK SHARP & DOHME LLC 2009-09-24 — — US disclosed
EP-1940407-A2 N-(4-OXO-3,4-DIHYDROQUINAZOLIN-2-YL)BUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS Merck & Co., Inc. (US) 2008-07-09 — — EP disclosed
WO-2007061677-A2 SPIROLACTAM ARYL CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2007-05-31 — — WO disclosed
WO-2007061676-A2 SPIROHYDANTOIN ARYL CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2007-05-31 — — WO disclosed
WO-2007038444-A2 N-(4-OXO-3,4-DIHYDROQUINAZOLIN-2-YL)BUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2007-04-05 — — WO disclosed
US-20040077667-A1 Quinazolinone derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-04-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150978-A1 QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER NQO2, NQO1, NDUFV2 TNKS2 357/4885KMT2A 2316/4885PDE10A 1255/4885
US-20090239870-A1 Spirohydantoin Aryl Cgrp Receptor Antagonists BDKRB1, BDKRB2, CALCRL TNKS2 3902/4885KMT2A 4002/4885PDE10A 1163/4885
US-20040077667-A1 Quinazolinone derivatives PARP1, PARP9, PARP2 TNKS2 32/4885KMT2A 1243/4885PDE10A 2013/4885
US-20100267633-A1 N-(4-Oxo-3,4-Dihydroquinazolin-2Yl) Butanamides as Androgen Receptor Modulators AR, FSHR, SHBG TNKS2 1609/4885KMT2A 2088/4885PDE10A 1835/4885
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 TNKS2 2840/4885KMT2A 4197/4885PDE10A 485/4885
US-20090247514-A1 Spirolactam aryl cgrp receptor antagonists CALCRL, BDKRB1, CALCR TNKS2 3049/4885KMT2A 4217/4885PDE10A 726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.